AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer

•AXL, marker of epithelial to mesenchymal transition, is expressed in metastatic colorectal cancer (mCRC).•AXL is associated with poor prognosis and shorter progression-free survival in patients with RAS wild-type (WT) mCRC.•AXL is a biomarker of both primary and acquired resistance to anti-epidermal growth factor receptor therapies in RAS WT mCRC.